NEW YORK – Investment banks William Blair and Cowen today separately initiated coverage of autoimmune disease diagnostics firm Exagen with Outperform ratings.
Cowen also set a price target on Exagen's stock at $17 per share.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.